Seagen (SGEN) Tops Q3 EPS by $3.00, Revenues Beat
Get Alerts SGEN Hot Sheet
EPS Growth %: +100.0%
Financial Fact:
Net income (loss): -31.75M
Today's EPS Names:
DGICA, UXIN, TOWN, More
Join SI Premium – FREE
Seagen (NASDAQ: SGEN) reported Q3 EPS of $3.50, $3.00 better than the analyst estimate of $0.50. Revenue for the quarter came in at $1.06 billion versus the consensus estimate of $508.49 million.
“Our third quarter and year-to-date strong financial performance was driven by product sales across our diverse portfolio of three marketed products as well as the positive financial impact of our recent collaborations with Merck on ladiratuzumab vedotin and TUKYSA,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Seagen. “We plan to report clinical and preclinical data across our programs at several medical meetings during the remainder of 2020. In addition, we are pursuing multiple regulatory submissions, including our TUKYSA MAA that is under review by the EMA, a planned tisotumab vedotin BLA in the U.S. and global marketing applications for PADCEV. With our significant financial resources, robust drug development pipeline, expanding footprint in Europe and strategic oncology collaborations, we are well-positioned to continue building Seagen to address the unmet medical needs of cancer patients around the globe.”
For earnings history and earnings-related data on Seagen (SGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) stock slips despite earnings beat
- Integer Holdings Corp (ITGR) Tops Q1 EPS by 2c ; Offers Guidance
- Donegal Group (DGICA) Tops Q1 EPS by 18c
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!